Stockwatch: Pantomime Season Comes Early
This article was originally published in Scrip
The critiques and revelations surrounding the business practices of Valeant Pharmaceuticals International Inc. continued last week with a second successive Monday morning press conference to refute some of the more recent accusations levelled against it. This was followed by a Friday morning marathon press conference held by one of its biggest hedge fund shareholders in an attempt to recover some of the value lost from the fund's Valeant holding. The revelations and refutations concerning Valeant have come to resemble a pantomime with the company in the role of villain, and the list of traditional pantomime characters was bolstered by companies reporting their third-quarter earnings last week.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.